TSX:CPHPharmaceuticals
Cipher Pharmaceuticals Q3 Margin Compression Tests Bullish Profitability Narrative
Cipher Pharmaceuticals (TSX:CPH) has put up another solid set of numbers for FY 2025 so far, with Q3 revenue of US$12.8 million and basic EPS of US$0.22, alongside trailing 12 month revenue of US$50.1 million and EPS of US$0.68. The company has seen quarterly revenue move from US$10.4 million in Q3 2024 to US$12.8 million in Q3 2025, while basic EPS shifted from roughly US$0.01 to US$0.22 over the same period. This gives investors a clear view of how the top and bottom lines have evolved...